161/297US=7 / Farmacologia
Wells BG, DiPiro JT, Schwinghammer TL, DiPiro Cecily V. Venous thromboembolism. In: ___. Pharmacotherapy handbook. 7th ed. New York: McGraw-Hill, 2008. p. 163-77. ISBN 978-0-07-148501-2.

TROMBOEMBOLISMO VENOSO; HEPARINA NAO FRACIONADA; FONDAPARINUX; INIBIDORES DIRETOS DA TROMBINA; VARFARINA; TROMBOLISE; TROMBECTOMIA; TROMBOEMBOLISMO VENOSO. PREVENCAO

162/297US=8 / Dermatologia
Pentland AP. Eicosanoids. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editores. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2008. p. 343-51. ISBN 978-0-07138076-0.

EICOSANOIDES; BIOQUIMICA; ACOES DE PROSTAGLANDINA; FORMACAO DE EICOSANOIDES; ACAO DAS EICOSANOIDES; INIBIDORES DE EICOSANOIDES

163/297US=80 / Biol/Mol
Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 161-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

LEUCEMIA MIELOIDE AGUDA; BIOMARCADORES; PHARMACOPROTEOMICS; ACIDO TRANS-RETINOICO; INIBIDORES DE QUINASE DE TIROSINA; HISTONA DEACETILASE INIBIDORES; INIBIDORES DE PROTEASSOMA

164/297US=84 / Biol/Mol
Risbridger GP, Butler C. TGF-B superfamily members in normal and tumor biology: activins and cancer progression. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 411-23. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

INIBIDORES; ACTIVINA; TUMORIGENESE; X SUBUNIDADE; SUBUNIDADE BA; METASTASE; ANGIOGENESE; SUPRESSAO IMUNITARIA

165/297US=84 / Biol/Mol
López-Casillas F, Vilchis-Landeros MM, Esparza-López J, Ponce-Castañeda MV, Velasco-Loyden NG, Juárez P, Montiel JL, Mendoza V. TGF-B superfamily members in normal and tumor biology: regulation of the transforming growth factor-B superfamily by betaglycan. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 451-61. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B TIPO III RECEPTOR; TGF-B; TGF-B INIBIDORES; TUBERCULOSE; BETAGLICAM; BETAGLICAM NULOS RATOS; ECOTODOMAIN DERRAMAMENTO; DESENVOLVIMENTO CABECA; INIBINA; NEFROPATIAS; XENOGRAFS TUMORAIS

166/297US=84-A / Biol/Mol
Datta PK, Mann JR. Development of inhibitors of transforming growth factor-B signaling for therapy: transforming growth factor-B (TGF-B) signaling inhibitors in cancer therapy. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 573-87. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; PEQUENA MOLECULA INIBIDORES; TRANSDUCAO DE SINAL; SUPRESSOR DE TUMOR; PROMOTOR DE TUMOR; BIOMARCADOR; TERAPIA DO CANCER

167/297US=84-A / Biol/Mol
Lacher MD, Korn WM, Akhurst RJ. Development of inhibitors of transforming growth factor-B signaling for therapy: reversal of EMT by small-molecule inibitors of TGF-B type I and II receptors: implications for carcinoma treatment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B RECEPTORES; PEQUENAS MOLECULAS INIBIDORES; EPITELIAL PARA MESEACHYMAL TRANSICAO; EMT; METASTASE; VIRUS COXSACKIE E RECEPTOR ADENOVIRUS; TERAPIA DO CANCRO ADENOVIRAL

168/297US=84-A / Biol/Mol
Bandyópadhyay A, Sun L. Development of inhibitors of transforming growth factor-B signaling for therapy: soluble TGF-B type III receptor suppresses malignant progression of human cancer cells. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 723-35. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

ANGIOGENESE; METALOPROTEINASE DE MATRIZ-9; METASTASE PULMONAR; METASTASE OSSEA; BETAGLICAM SOLUVEL; TGF-B; TGF-B TIPO DE INIBIDORES DO RECEPTOR III; TUMORIGENESE

169/297US=84-A / Biol/Mol
Hoffmann FM, Cui Q, Lim SK, Zhao BM. Development of inhibitors of transforming growth factor-B signaling for therapy: targeting smad-dependent TGF-B signaling with peptide aptamers. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 737-56. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

APTAMEROS PEPTIDEO; MOTIVO DE PROTEINA; PROTEINA ANDAIME; SMAD; TGF-B INIBIDORES

170/297US=86 / Biol/Mol
Melet A, Song K, Bucur O, Jagani Z, Grassian AR, Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 47-79. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

VIAS APOPTOTICAS; PROGRESSAO TUMORAL; TERAPIA DE CANCER; APOPTOSE; INIBIDORES; TRANSDUCAO DE SINAL; ONCOGENE; MAQUINARIA APOPTOTICA; DROGAS QUIMIOTERAPICAS; RESISTENCIA A DROGA

171/297US=86 / Biol/Mol
Tan TT, White E. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 81-104. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

SEGMENTACAO TERAPEUTICO; VIAS DE MORTE EM CANCER; MECANISMOS; MORTE CELULAR; CELULAS CANCERIGENAS; APOPTOSE; QUIMIOTERAPIA; TERAPIA ALVO; FAMILIA BCL-2; RECEPTORES DE MORTE; INIBIDORES DO SINAL DE TRANSDUCAO

172/297US=86 / Biol/Mol
Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HAC inhibitor-induced apoptosis. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 261-98. (Advances in Experimental Medicina and Biology volume 615) ISBN 978-1-4020-6553-8.

INIBIDORES DE HISTONA DESACETILASE; CANCER; APOPTOSE INDUZIDA POR INIBIDORES; INIBIDORES HDAC; HAT; SAHA; MS-275; TSA; TRAIL; CASPASE

173/297US=90 / Biol/Mol
Bennett HL, Brummer T, Timpson P, Patterson KI, Daly RJ. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: signaling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 235-55. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

SRC; RAS; RAF; ERK; PI3-QUINASE; PTEN; EGFR INIBIDORES; LOOPS DE FEEDBACK; C-CBL; ENDOCITOSE

174/297US=90 / Biol/Mol
Eberhard DA. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR mutations, other molecular alterations related to sensitivity to EGFR-targeted therapies in non-small cell lung cancer. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 293-336. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DE QUINASE DE TIROSINA; DIAGNOSTICOS MOLECULARES; MUTACOES; HIBRIDACAO IN SITU FLUORESCENTE; IMUNOHISTOQUIMICA; CANCER DE PULMAO

175/297US=90 / Biol/Mol
Thomson S, Haley JD, Yauch R. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: cellular sensitivity to EGF receptor inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 353-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EGFR; HER2; HER3; ERLOTINIB; A TRANSICAO EPITELIAL MESENQUIMAL; INIBIDORES DE QUINASE DE TIROSINA

176/297US=98 / Biol/Mol
Egger L. Caspase-independent apoptotic cell death. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 93-108. ISBN 978-084939192-7.

CASPASE-INDEPENDENTE DE MORTE CELULAR POR APOPTOSE; INIBICAO DA CASPASE; SINTETICOS INIBIDORES DE CASPASES; CASPASE-MORTE CELULAR INDEPENDENTE

177/297US=1 / Química
Stillway LW. Bioenergética e metabolismo oxidativo. In: Baynes JW, Dominiczak MH. Bioquímica médica. 2ª ed. Rio de Janeiro: Elsevier, 2007. p. 101-20. ISBN 85-3522298-2.

OXIDACAO; TAXA METABOLICA BASAL; ENERGIA LIVRE DE GIBBS; SINTESE MITOCONDRIAL DE ATP; SISTEMA DE TRANSPORTE DE ELETRONS MITOCONDRIAL; RAZAO P:O; INIBIDORES DO METABOLISMO OXIDATIVO; REGULACAO DA FOSFORILACAO OXIDATIVA

178/297US=10 / Dermatologia
Pires MC, Medeiros LRA. Terapia sistêmica em dermatologia. In: Sittart JAS, Pires MC. Dermatologia na prática médica. São Paulo: Roca, 2007. p. 635-61. ISBN 85-7241695-5.

CORTICOSTEROIDES SISTEMICOS; ANTIBIOTICOS; ANTIFUNGICOS; CLOROQUINA; CICLOSPORINA A; TACROLIMO; AZATIOPRINA; MICOFENOLATO DE MOFETILA; TALIDOMIDA; INTERFERON; IMUNOGLOBULINA HIPERIMUNE INTRAVENOSA; INIBIDORES DOS LEUCOTRIENOS; IMUNOMODULADORES BIOLOGICOS

179/297US=7 / Transplante
Pollinger HS, Burns JM, Casingal VP, Gores PF. The basic biology of cell therapy: current immunosuppressive drugs and clinical use. In: Halberstadt C, Emerich D, editors. Cellular transplantation: from laboratory to clinic. Amsterdam: Elsevier, 2007. p. 13-28. ISBN 978-0-12-369415-7.

TERAPIA CELULAR; BIOLOGIA BASICA; DROGAS IMUNOSSUPRESSORAS; RESPOSTA ALOIMUNE; AZATIOPRINA; CICLOSPORINA; TACROLIMUS; SIROLIMUS; MICOFENOLATO DE MOFETIL; CORTICOSTEROIDES; DROGAS PROTEICAS; ANTI-SOROS POLICLONAIS; ANTICORPOS MONOCLONAIS; ANTI-CD-3; ANTI-CD-25; ANTI-CD-20; ALEMTUZUMAB; INIBIDORES DE CO-ESTIMULACAO; DESOXISPERGUALINA

180/297US=111-A / Câncer
Barrett SV, Cassidy J. Conventional chemotherapeutics. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 1191-8. ISBN 978-0-470-01852-1.

CANCER. TERAPIA; QUIMIOTERAPICOS CONVENCIONAIS; ANTIMETABOLITOS; AGENTES ALQUILANTES; AGENTES DE PLATINA; INIBIDORES DA TOPOISOMERASE; ANTIBIOTICOS ANTITUMORAIS; AGENTES ANTIMICROTUBULOS

Primeira | Anterior | Próxima | Última